MedTrace Logo

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

NCT05983445 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 313

Last updated 2024-12-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).

Conditions

  • Acute Gout Arthritis

Interventions

DRUG

genakumab

200mg s.c.

DRUG

placebo for Diprospan

i.m.

DRUG

placebo for genakumab

s.c.

DRUG

Diprospan

7mg i.m.

Sponsors & Collaborators

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-11
Primary Completion
2024-04-03
Completion
2024-04-03
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05983445 on ClinicalTrials.gov